Donor cells take on tough leukemia in new trial
NCT ID NCT07026942
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially modified immune cells from a healthy donor to attack the cancer. The first part finds the safest dose, and the second part checks how well it works. About 42 people will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED / REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.